Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	52.32	23.96
Short-Term Investments	86.09	86.68
Cash & Short-Term Investments	138.41	110.63
Cash Growth	25.11%	-
Other Receivables	0.54	0.59
Receivables	0.54	0.59
Prepaid Expenses	0.71	0.31
Other Current Assets	3.91	2.86
Total Current Assets	143.56	114.39
Property, Plant & Equipment	2.32	0.09
Long-Term Investments	-	7.49
Other Long-Term Assets	3	2.55
Total Assets	148.88	124.52
Accounts Payable	3.76	2.28
Accrued Expenses	9.89	6.47
Current Portion of Leases	0.44	-
Total Current Liabilities	14.09	8.74
Long-Term Leases	1.23	-
Total Liabilities	15.32	8.74
Common Stock	0.02	0.01
Additional Paid-In Capital	26.55	5.43
Retained Earnings	-265.36	-180.16
Comprehensive Income & Other	0.13	0.2
Total Common Equity	-238.66	-174.52
Shareholders' Equity	133.57	115.78
Total Liabilities & Equity	148.88	124.52
Total Debt	1.67	-
Net Cash (Debt)	136.74	118.12
Net Cash Growth	15.76%	-
Net Cash Per Share	7.32	22.72
Filing Date Shares Outstanding	23.61	5.33
Total Common Shares Outstanding	23.61	5.33
Working Capital	129.47	105.64
Book Value Per Share	-10.11	-32.77
Tangible Book Value	-238.66	-174.52
Tangible Book Value Per Share	-10.11	-32.77
Machinery	0.16	0.11
Construction In Progress	0.68	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q